Search the GHTC website

Global health R&D delivers for Vermont

US government investment in global health R&D has delivered

Amount
$1.2 million
to Vermont research institutions
Global health R&D at work in Vermont

The University of Vermont’s Vaccine Testing Center is designing a research platform upon which new treatments for cryptosporidiosis can be tested in humans. Cryptosporidiosis, or crypto for short, is an infection caused by Cryptosporidium, a single-celled intestinal parasite found in soil, food, and water. Crypto is a leading cause of severe diarrhea in infants and young children in low-income countries. It also causes significant illness and death in immunocompromised individuals. No vaccines exist to treat or prevent the infection and there are limited treatment options. In many parts of the world, crypto is associated with poor childhood nutrition and stunted growth. Past work by the center has focused on how crypto contributes to the vicious cycle of diarrhea, infectious diseases, and malnutrition.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Case study photo: PATH/Miguel Alvarez